SEC Stock Data Quick Answer Allogene Therapeutics, Inc. reported Cash and Equivalents of $51.69 million for fiscal year 2025. Allogene Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $51.69M -31.3% 2024 $75.22M -9.5% 2023 $83.16M +20.1% 2023 $69.25M -55.3% 2023 $154.76M +40.8% 2023 $109.93M +77.6% 2022 $61.90M -16.7% 2022 $74.36M … Read more
Quick Answer Allogene Therapeutics, Inc. reported Total Assets of $415.90 million for fiscal year 2025. Allogene Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $415.90M -24.2% 2024 $548.71M -14.6% 2023 $642.84M -9.9% 2023 $713.41M -7.7% 2023 $773.01M +3.1% 2023 $750.13M -8.7% 2022 $821.58M -8.1% 2022 $894.48M -6.4% 2022 $955.62M … Read more
Quick Answer Allogene Therapeutics, Inc. reported Diluted EPS of $0.87 per share (loss) for fiscal year 2025. Allogene Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.87 +34.1% 2024 -$1.32 +36.8% 2023 -$2.09 +12.2% 2022 -$2.38 -77.6% 2021 -$1.34 +35.6% 2020 -$2.08 -13.7% 2019 -$1.83 — Quarterly Diluted EPS … Read more
Quick Answer Allogene Therapeutics, Inc. reported Net Income of -$190.89 million for fiscal year 2025. Allogene Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$190.89M +25.9% 2024 -$257.59M +21.3% 2023 -$327.26M +3.9% 2022 -$340.41M -87.0% 2021 -$182.05M +27.2% 2020 -$250.22M -35.6% 2019 -$184.59M +12.7% 2018 -$211.50M -10575150.0% 2017 -$2.0K … Read more
Quick Answer Allogene Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025. Allogene Therapeutics, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $0.00 -100.0% 2024 $22.0K -76.8% 2023 $95.0K -39.1% 2022 $156.0K -99.9% 2021 $114.09M — 2020 $0.00 — 2019 $0.00 — Quarterly Revenue (ASC … Read more
Quick Answer Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025. Allogene Therapeutics, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $0.00 -100.0% 2024 $22.0K -76.8% 2023 $95.0K -39.1% 2022 $156.0K -99.9% 2021 $114.09M — 2020 $0.00 — 2019 $0.00 — Quarterly Total Revenue Quarter Ending Total … Read more
Quick Answer Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025. Allogene Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $0.00-100.0% $22.0K-76.8% $95.0K-39.1% $156.0K-99.9% $114.09M $0.00 Revenue (ASC 606) $0.00-100.0% $22.0K-76.8% $95.0K-39.1% $156.0K-99.9% $114.09M $0.00 Net Income -$190.89M+25.9% -$257.59M+21.3% -$327.26M+3.9% -$340.41M-87.0% -$182.05M+27.2% -$250.22M-35.6% Diluted … Read more
Quick Answer Allegion plc reported Shares Outstanding of 86.07 million shares for fiscal year 2025. Allegion plc Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 86.07M -0.2% 2024 86.25M -1.4% 2023 87.50M -0.4% 2022 87.85M -0.4% 2021 88.22M -3.3% 2020 91.21M -1.6% 2019 92.72M — Quarterly Shares Outstanding Quarter Ending Shares … Read more
Quick Answer Allegion plc reported Operating Income of $859.50 million for fiscal year 2025. Allegion plc Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $859.50M +10.1% 2024 $780.70M +10.2% 2023 $708.40M +20.8% 2022 $586.40M +10.6% 2021 $530.20M +31.4% 2020 $403.50M -28.6% 2019 $565.10M +7.5% 2018 $525.80M +6.8% 2017 $492.50M +13.4% 2016 … Read more
Quick Answer Allegion plc reported Stockholders Equity of $2.07 billion for fiscal year 2025. Allegion plc Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $2.07B +37.8% 2024 $1.50B +13.8% 2023 $1.32B +40.0% 2022 $941.80M +24.1% 2021 $759.10M -8.5% 2020 $829.40M +9.5% 2019 $757.40M +16.3% 2018 $651.00M +62.1% 2017 $401.60M +254.5% 2016 … Read more